Due to the ubiquity of epoxy resin compounds and their potential role in increasing the risk for reproductive dysfunction and cancer, the need for an assessment of human exposure is urgent. Therefore, we developed a method for measuring bisphenol A (BPA) and bisphenol A diglycidyl ether (BADGE) metabolites in human blood samples using high-performance liquid chromatography–electrospray ionization mass spectrometry (LC–MS). Human blood samples were processed using enzymatic deconjugation of the glucuronides followed by a novel sample preparation procedure using a solid-phase-cartridge column. This selective analytical method permits rapid detection of the metabolites, free BPA and a hydrolysis product of BADGE (BADGE-4OH) with detection limits in the low nanogram per milliliter range (0.1 ng ml−1 of BPA and 0.5 ng ml−1 of BADGE-4OH). The sample extraction was achieved by Oasis HLB column on gradient elution. The recoveries of BPA and BADGE-4OH added to human plasma samples were above 70.0% with a standard deviation of less than 5.0%. This selective, sensitive and accurate method will assist in elucidating potential associations between human exposure to epoxy-based compounds and adverse health effects.
[Show abstract][Hide abstract] ABSTRACT: The plastic monomer and plasticizer bisphenol A (BPA) is one of the highest volume chemicals produced worldwide. BPA is used in the production of polycarbonate plastics and epoxy resins used in many consumer products. Here, we have outlined studies that address the levels of BPA in human tissues and fluids. We have reviewed the few epidemiological studies available that explore biological markers of BPA exposure and human health outcomes. We have examined several studies of levels of BPA released from consumer products as well as the levels measured in wastewater, drinking water, air and dust. Lastly, we have reviewed acute metabolic studies and the information available about BPA metabolism in animal models. The reported levels of BPA in human fluids are higher than the BPA concentrations reported to stimulate molecular endpoints in vitro and appear to be within an order of magnitude of the levels needed to induce effects in animal models.
[Show abstract][Hide abstract] ABSTRACT: A rapid and sensitive ultra performance liquid chromatography-tandem mass spectrometry with electrospray ionization in the positive mode (UPLC-(ESI) MS/MS) method was developed for the simultaneous determination of 16 bisphenol A diglycidyl ether (BADGE), novolac glycidyl ether (NOGE) and related compounds in canned foods. Three non-commercially available standards bisphenol F (2, 3-dihydroxypropyl) glycidyl ether (BFDGE·H2O), bisphenol F (3-chloro-2-hydroxypropyl) glycidyl ether (BFDGE·HCl) and bisphenol F (3-chloro-2-hydroxypropyl) (2,3-dihydroxypropyl) ether (BFDGE·H2O·HCl) were synthesized and used for qualitative analysis. Quantification of 13 analytes was carried out in multiple reaction monitoring mode using an external calibration, and the interference of matrixes was reduced by the matrix-matched calibration. The parameters of liquid chromatography and mass spectrometry were optimized to obtain maximum selectivity and sensitivity. The validation data obtained from oil-based and aqueous-based canned food matrixes showed low limit of detection, which ranged from 0.24 to 1.84 ng g−1, acceptable recovery (62.36–101.77 %) and good repeatability (RSD <10), all indicated this optimized method was suitable for the migration evaluation of BADGE, NOGE and their derivatives from can lacquer into food. Finally, this method was applied to the analysis of these compounds at low levels in diverse commercial canned samples.
European Food Research and Technology 08/2012; 235(2). DOI:10.1007/s00217-012-1734-7 · 1.56 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.